Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRJSP8)

Drug Name
Orlistat Drug Info
Synonyms
orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247; Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN
Therapeutic ClassAntiobesity Agents
Cross-matching ID
PubChem CID
3034010
ChEBI ID
CHEMBL175247
CAS Number
CAS 96829-58-2
TTD Drug ID
D0T9TJ
ACDINA Drug ID
D00491

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.52 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis 2.23 0.00e+0 18/22 (81.82%) HMGCS1;ACAT2;IDI1;...
PPAR signaling pathway 2.13 0.00e+0 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Biosynthesis of unsaturated fatty acids 2.13 0.00e+0 21/27 (77.78%) SCD;ELOVL6;FADS1;...
Valine, leucine and isoleucine degradation 2.05 2.30e-3 42/48 (87.5%) HMGCS1;ACAT2;AACS;...
Amino sugar and nucleotide sugar metabolism 2.05 1.91e-3 38/48 (79.17%) GNE;CMAS;AMDHD2;...
Butanoate metabolism 1.96 1.64e-3 23/28 (82.14%) HMGCS1;ACAT2;AACS
Cholesterol metabolism 1.85 2.15e-2 44/50 (88%) LDLR;STAR;LIPA;...
Fatty acid biosynthesis 1.83 3.19e-2 16/18 (88.89%) FASN;ACACA;ACSL3;...
Synthesis and degradation of ketone bodies 1.83 2.98e-2 9/10 (90%) HMGCS1;ACAT2
Graft-versus-host disease -1.81 1.79e-2 32/42 (76.19%) PRF1;HLA-DRB1;HLA-G;...
Autoimmune thyroid disease -2.07 0.00e+0 46/53 (86.79%) IFNA17;PRF1;HLA-DRB1;...
Allograft rejection -2.16 0.00e+0 32/38 (84.21%) PRF1;HLA-DRB1;HLA-G;...
Ribosome biogenesis in eukaryotes -2.19 0.00e+0 52/108 (48.15%) IMP4;RPP30;FBL;...
Proteasome -2.31 0.00e+0 44/46 (95.65%) PSMD2;ADRM1;PSMD1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H